In one paragraphArticle in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Alisa KachikisDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-0358-5107 Collrane FrivoldDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-2000-5429 Mindy PikeDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-7153-868X Jonathan C ReedDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-4425-7636 Kittredge McVeyDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.ORCID 0009-0003-8632-6748 Erica ClarkDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0009-0002-7241-159X Clarice MauerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Sandra McAteerDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Ioana Maria SaidacDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.
Alex HartelooDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Grace MarshallDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.
Linda O EckertDepartment of Obstetrics and Gynecology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-1357-8405 Alexander L GreningerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-7443-0527 Janet A EnglundDepartment of Pediatrics, Division of Pediatric Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-1134-4178 Helen Y ChuDepartment of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.ORCID 0000-0001-8502-9600 Funding
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0MProtection of at-risk low birth weight infants against influenza via maternal antibodyK23AI153390 · NIAID · UNIVERSITY OF WASHINGTON · PI KACHIKIS, ALISA · 2021 to 2025
$942kNational Institute of Allergy and Infectious DiseasesNCATS NIH HHS UL1 TR002319NIAID NIH HHS K23 AI153390NIHUniversity of Washington Institute of Translational Health Science
6 · The paper itselfAbstract
Respiratory syncytial virus (RSV) vaccination is recommended in pregnancy. Limited data exist regarding antibody (Ab) durability to inform revaccination timing. We conducted prospective cohort studies among pregnant and older adults after first RSV vaccination in 2023-2024. Longitudinal samples from 50 pregnant (36 vaccinated) and 16 vaccinated older adults were collected until 12-15 months after vaccination and tested for RSV binding and neutralizing Ab. Mean Ab levels 12-15 months after vaccination were similar between vaccinated maternal and older adult participants (P = .73), suggesting Ab durability up to 1 year after maternal RSV vaccination. RSV binding and neutralizing Ab titers were strongly correlated (R = .73).
Indexed as
Antibodies, ViralRespiratory Syncytial Virus, HumanRespiratory Syncytial Virus InfectionsRespiratory Syncytial Virus VaccinesAdultAgedAntibodies, NeutralizingFemaleHumansLongitudinal StudiesPostpartum PeriodPregnancyProspective StudiesVaccinationAntibodies, NeutralizingAntibodies, ViralRespiratory Syncytial Virus Vaccinesantibody durabilitymaternal immunizationRespiratory syncytial virus (RSV)RSV vaccine in pregnancy
Identifiers
PMID41885612
PMCPMC13431677
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390